T0	Participants 36 82	recipients of extended criteria donor kidneys.
T1	Participants 84 158	Patients in the BENEFIT-EXT study received extended criteria donor kidneys
T2	Participants 271 385	Patients who remained on assigned therapy through year 3 were eligible to enter a long-term extension (LTE) study.
T3	Participants 386 503	Three hundred four patients entered the LTE (n = 104 MI; n = 113 LI; n = 87 CsA), and 260 continued treatment through
T4	Participants 523 530	n = 100
T5	Participants 1013 1090	n = 1 CsA); two of three PTLD cases in the LI group were in patients who were